Gene · 5362
Papers4,083
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
501 to 520 of 4,083
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| CASZ1: Current Implications in Cardiovascular Diseases and Cancers. | Biomedicines | 2023 | 37509718 | PubTator, text mining | PubMed |
| Domperidone Inhibits Clostridium botulinum C2 Toxin and Bordetella pertussis Toxin. | Toxins (Basel) | 2023 | 37505681 | PubTator, text mining | PubMed |
| Perturbed epigenetic transcriptional regulation in AML with IDH mutations causes increased susceptibility to NK cells. | Leukemia | 2023 | 37495775 | PubTator, text mining | PubMed |
| Macular hole Delphi consensus statement (MHOST). | Acta Ophthalmol | 2023 | 37493073 | PubTator, text mining | PubMed |
| Exceedingly Rare Bilateral Synchronous Germ Cell Testicular Tumors With Different Histopathological Features. | Cureus | 2023 | 37492037 | PubTator, text mining | PubMed |
| Impact of AKT1 on cell invasion and radiosensitivity in a triple negative breast cancer cell line developing brain metastasis. | Front Oncol | 2023 | 37483521 | PubTator, text mining | PubMed |
| Aqueous Fluid Transcriptome Profiling Differentiates Between Non-Neovascular and Neovascular AMD. | Invest Ophthalmol Vis Sci | 2023 | 37471072 | PubTator, text mining | PubMed |
| Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer's disease. | Mol Neurodegener | 2023 | 37468915 | PubTator, text mining | PubMed |
| Association of OCT biomarkers and visual impairment in patients with diabetic macular oedema with vitreomacular adhesion. | PLoS One | 2023 | 37463157 | PubTator, text mining | PubMed |
| Chemotherapy-induced exosomal circBACH1 promotes breast cancer resistance and stemness via miR-217/G3BP2 signaling pathway. | Breast Cancer Res | 2023 | 37461019 | PubTator, text mining | PubMed |
| Real-world study to evaluate the efficacy and safety of intravitreal brolucizumab for refractory neovascular age-related macular degeneration. | Sci Rep | 2023 | 37452068 | PubTator, text mining | PubMed |
| Transcriptomic analysis of spinal cord regeneration after injury in Cynops orientalis. | Neural Regen Res | 2023 | 37449639 | PubTator, text mining | PubMed |
| Research Methods and New Advances in Drug-Drug Interactions Mediated by Renal Transporters. | Molecules | 2023 | 37446913 | PubTator, text mining | PubMed |
| Comparison of widefield swept-source optical coherence tomographic angiography and fluorescein fundus angiography for detection of retinal neovascularization with diabetic retinopathy. | BMC Ophthalmol | 2023 | 37438731 | PubTator, text mining | PubMed |
| Vasoreactivity of the optic nerve head, nailfold, and facial skin in response to cold provocation in normal-tension glaucoma patients. | BMC Ophthalmol | 2023 | 37438715 | PubTator, text mining | PubMed |
| Subclinical microvascular changes in ANCA-vasculitides: the role of optical coherence tomography angiography and nailfold capillaroscopy in the detection of disease-related damage. | Orphanet J Rare Dis | 2023 | 37430363 | PubTator, text mining | PubMed |
| Epidemic retinitis during the COVID-19 pandemic. | Indian J Ophthalmol | 2023 | 37417120 | PubTator, text mining | PubMed |
| Characteristics of tear meniscus using a spectral domain optical coherence tomography in medically controlled glaucoma. | Indian J Ophthalmol | 2023 | 37417108 | PubTator, text mining | PubMed |
| Expression of OCT4 isoforms is reduced in primary colorectal cancer. | Front Oncol | 2023 | 37409260 | PubTator, text mining | PubMed |
| Editorial: Application of nanotechnology in diagnosis and/or therapy of non-small cell lung cancer. | Front Oncol | 2023 | 37397385 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5362/papers?page=26